DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR LEUKERAN
Clinical Trials for Leukeran
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00875667 | A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Active, not recruiting | Celgene Corporation | Phase 2 | To evaluate the safety and efficacy of lenalidomide versus investigator choice in patients with relapsed or refractory Mantle Cell Lymphoma. |
| NCT00910910 | Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial) | Active, not recruiting | Celgene Corporation | Phase 3 | The purpose of this study is to determine the safety and efficacy of lenalidomide as a first line therapy in treating patients with B-cell Chronic Lymphocytic Leukemia. This study will compare the effects (good and bad) of lenalidomide with chlorambucil. |
| NCT01088048 | Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chron | Completed | Gilead Sciences | Phase 1 | This study will evaluate the safety and clinical activity of idelalisib in combination with an anti-CD20 monoclonal antibody (mAb), a chemotherapeutic agent, an mTOR inhibitor, a protease inhibitor, an antiangiogenic agent, and/or an immunomodulatory agent in participants with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL). |
| NCT01657955 | Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia | Unknown status | Shandong Lanjin Pharmaceuticals Co.,Ltd | Phase 3 | The purpose of this study is to determine whether bendamustine is effective in the treatment of initial treatment of Chronic Lymphocytic Leukemia (CLL). |
| NCT01678430 | A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment | Recruiting | Chugai Pharma USA | Phase 3 | The purpose of this study is to compare ofatumumab & chlorambucil (O-Chl) versus ofatumumab & bendamustine (O-B) in patients with Chronic Lymphocytic Leukaemia who are considered not fit enough for rituximab, fludarabine & cyclophosphamide (R-FC). |
| NCT01678430 | A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment | Recruiting | GlaxoSmithKline | Phase 3 | The purpose of this study is to compare ofatumumab & chlorambucil (O-Chl) versus ofatumumab & bendamustine (O-B) in patients with Chronic Lymphocytic Leukaemia who are considered not fit enough for rituximab, fludarabine & cyclophosphamide (R-FC). |
| NCT01678430 | A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment | Recruiting | Napp Pharmaceuticals Limited | Phase 3 | The purpose of this study is to compare ofatumumab & chlorambucil (O-Chl) versus ofatumumab & bendamustine (O-B) in patients with Chronic Lymphocytic Leukaemia who are considered not fit enough for rituximab, fludarabine & cyclophosphamide (R-FC). |
| Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Leukeran
Clinical Trial Locations for Leukeran
Trials by Country
Clinical Trial Progress for Leukeran
Clinical Trial Phase
Clinical Trial Sponsors for Leukeran
Sponsor Name
